Article
Real-world data on the use of asciminib in chronic-phase chronic myeloid leukemia after two or more prior tyrosine kinase inhibitors: Results of the Turkish managed access program along with a literature review.
Leukemia research - 1 Jul 2026
Özmen Deniz, Kürekçi Derya Deniz, Özkocaman Vildan, Altındağ Avcı Burcu, Bozer Denis Sabriye, Kasar Mutlu, Şahin Osman, Korkmaz Gülten, Can Ferda, Pepeler Mehmet Sezgin, Erkut Nergiz, Kırkızlar Onur, Yel Uygun Kübra, Bulduk Tuba, Yıldırım Murat, Aslaner Müzeyyen, Altındal Şermin, Arikan Fatma, Dal Mehmet Sinan, Deveci Burak, Güler Nil, Güneş Ahmet Kürşad, Gürkan Emel, Özbalcı Demircan, Öztürk Osman Can, Ülküden Burcu, Yılmaz Hüseyin, Yüksel Meltem Kurt, Aylı Meltem, Demir Ahmet Muzaffer, Özatlı Düzgün, Özkalemkaş Fahir, Saydam Güray, Sönmez Mehmet, Turgut Burhan, Turgut Mehmet, Ünal Ali, Eşkazan Ahmet Emre
Abstract excerpt
BACKGROUND: Asciminib is a first-in-class STAMP inhibitor used in treating patients with chronic-phase chronic myeloid leukemia (CML-CP). Although its efficacy has been demonstrated in clinical trials, real-world data remain limited, particularly in heavily pretreated populations. METHODS: This multicenter, retrospective study included patients with CML-CP from 25 centers in Turkey who received asciminib through...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.